Skip Lot Testing for Supplements — When You Can Reduce Testing

Not every lot of every ingredient needs full testing. 21 CFR 111.75(d) gives supplement manufacturers a legal path to reduce testing frequency — but the bar is high, the documentation burden is real, and FDA inspectors will scrutinize your justification. This guide explains exactly how to build a defensible skip-lot program.

Quick answer

Skip lot testing allows you to test a subset of incoming ingredient lots instead of every lot, provided you have documented scientific justification. You typically need 5-10 consecutive lots with passing results before you can reduce frequency. Identity, potency, and microbial testing are the hardest to reduce. Heavy metal and pesticide testing are the most common candidates for skip-lot programs. FDA expects a written SOP, statistical analysis, and a defined escalation procedure if a skipped lot is ever found out of specification.

The regulation: 21 CFR 111.75(d)

Here is the exact regulatory text:

"You are not required to conduct tests to determine whether the specifications are met for the identity, purity, strength, and composition for components that are dietary ingredients... if you... rely on a certificate of analysis from the supplier... provided that:

1. You first qualify the supplier by establishing the reliability of the supplier's COA through confirmation of the results of the supplier's tests or examinations;
2. The COA includes a description of the test or examination method used, limits of the test or examination, and actual results of the test or examination;
3. You maintain documentation of how you qualified the supplier;
4. You periodically re-confirm the supplier's COA; and
5. Your quality control personnel review and approve the documentation."

This is commonly called "skip lot testing" or "reduced testing." The regulation does not use those terms — it uses "rely on a certificate of analysis from the supplier." But the practical effect is that you test fewer lots.

⚠️ Note

21 CFR 111.75(d) applies to dietary ingredients and components. It does NOT apply to finished product batch testing (21 CFR 111.75(c)). Every finished product batch must still be tested for identity, purity, strength, and composition unless a comparable exemption applies. Do not conflate incoming ingredient skip-lot with finished product release testing.

Which tests can you reduce and which you cannot

Not all tests are equally suitable for skip-lot programs. Here is a practical breakdown:

Tests most commonly reduced

Tests hardest to reduce

How many clean lots do you need

FDA has not published a specific number, but industry practice and guidance from trade associations (AHPA, CRN, NPA) converge on:

The principle is simple: the more lots that pass, the stronger your statistical justification that the supplier's process is in control. Ten passing lots gives you roughly 80% confidence that at least 90% of future lots will pass (based on binomial probability).

Statistical justification

A defensible skip-lot program includes a statistical rationale. The simplest approach:

1. Calculate your lot pass rate: (passing lots / total lots tested) x 100.
2. Determine your acceptable risk level. For example, you might accept a 95% probability that a skipped lot would have passed if tested.
3. Calculate the confidence interval around your pass rate using binomial distribution.
4. Set your skip frequency based on the lower confidence bound.

A worked example: You have tested 15 consecutive lots of an herbal extract for heavy metals and all passed. Your observed pass rate is 100%. The 95% lower confidence bound for 15 out of 15 passing is approximately 82% (using the rule of three: 3/15 = 20% failure rate upper bound). This means you can be 95% confident that at least 82% of future lots will pass.

If you set a threshold of 90% lower confidence bound, you need more lots. With 30 passing lots, the 95% lower confidence bound rises to approximately 91%. This would justify a more aggressive skip ratio.

💡 Note

Keep it simple. FDA inspectors are not statisticians. They want to see: (a) you documented how many lots you tested, (b) all passed, (c) you test every Nth lot and document the results, and (d) you have a plan for what happens if a skipped lot is found OOS.

Documentation FDA expects

Your skip-lot SOP should include:

1. Supplier qualification record. How you initially confirmed the supplier's COA. Which lots you tested. Which methods you used. What the results were. Date of initial qualification.

2. Skip-lot justification memo. How many consecutive lots passed. The statistical confidence this provides. Why the risk of the specific contaminant is low for this specific supplier. Signed by QC personnel.

3. Ongoing monitoring plan. How often you will re-test (e.g., every 3rd lot, every 5th lot). The trigger for returning to 100% testing (typically any OOS result).

4. Re-qualification schedule. Annual re-qualification is standard, meaning you test at least one lot per year even if the skip interval would have fallen between re-qualifications.

5. Escalation procedure. What happens if a tested lot fails. Immediately return to 100% testing. Investigate root cause. Notify the supplier. Require corrective action before re-entering skip-lot. Document everything.

6. Annual review. Each year, review all skip-lot test results. Confirm the program is still appropriate. Document the review with signature and date.

When skip lot testing fails

Common failure modes:

1. Supplier changes sourcing without telling you. A botanical supplier switches farms mid-contract. The heavy metal profile from the new farm differs from the qualified farm. Your next tested lot (1 in 3) catches it, but two skipped lots already went into production. Now you are testing finished product for heavy metals retroactively. This is why supplier audits and supply chain transparency matter.

2. Seasonal variation. Pesticide residues in botanicals vary by growing season. A skip-lot program validated on winter harvest lots may fail when summer lots arrive with higher residues.

3. Complacency. Three years of passing skip-lot results. No one notices the re-qualification date passed. FDA arrives and finds an expired program. This is a 483 observation waiting to happen.

4. Method drift. The supplier's in-house method produced passing results, but when you tested the qualifying lots, you used a more sensitive external lab method. Subsequent skip-lot testing uses a different lab with a different method, and the results are not comparable.

Related guides

• GMP compliance checklist — 21 CFR 111
• How to verify a supplier COA
• First batch testing checklist
• Finished product testing requirements
• Sourcing clean ingredients — testing before you buy

FAQ

Q: Can I skip identity testing under 21 CFR 111.75(d)?

A: No. 21 CFR 111.75(a)(1)(ii) requires you to conduct at least one identity test on each incoming dietary ingredient lot before use in manufacturing. This requirement is separate from the reduced testing provisions in 111.75(d). You must identify every lot. You may choose which identity test (HPTLC, microscopy, organoleptic, etc.), but you must do it.

Q: How many lots can I skip before FDA considers it unacceptable?

A: FDA has not published a specific ratio. Industry practice rarely exceeds 1 in 5 for heavy metals and 1 in 3 for pesticides. Skipping more than 4 out of 5 lots increases your regulatory risk. The conservative approach is 1 in 3 for low-risk tests and every lot for identity, potency, and microbial.

Q: Does skip lot testing apply to finished product batches?

A: Not in the same way. 21 CFR 111.75(c) requires finished product testing to verify that specifications are met. 21 CFR 111.75(d) applies only to components and dietary ingredients. For finished products, you may use process validation and in-process controls to reduce finished product testing, but this is a different regulatory pathway (21 CFR 111.75(c)(3)).

Q: What happens if my skipped lot is later found to be contaminated?

A: This triggers a full investigation under 21 CFR 111.113 (or your CAPA procedure). You must identify all finished product batches made with that ingredient lot, test retained samples or finished product, determine whether a recall is necessary, report to FDA if required, and immediately suspend the skip-lot program for that supplier until root cause is identified and corrected.

Q: Can I use my supplier's skip-lot program as justification for my own?

A: No. You must independently qualify each supplier under 111.75(d)(1). You may use the supplier's data as supporting evidence, but you must confirm their results through your own testing for the initial qualification lots. Your skip-lot program is your regulatory responsibility, not the supplier's.

Quick Reference

Regulation: 21 CFR 111.75(d) — Reduced testing for components and dietary ingredients

Minimum clean lots before reducing:

Typical skip ratios after qualification:

Documentation required: Supplier qualification SOP, skip-lot justification memo, monitoring plan, re-qualification schedule, escalation procedure, annual review records.

FDA inspection focus: Written justification, statistical rationale, recent test records, that identity testing is NOT skipped, and that the program has not lapsed.

Get lab testing quotes →